Rat liver fibrosis regresses better with pegylated interferon α2b and ursodeoxycholic acid treatments than spontaneous recovery

Liver International

Volumn 26, Issue 2, 2006, Pages 261-268

  Tasci, IIker ^a   Mas, Mehmet R ^a   Vural, Sevil A ^b   Comert, Bilgin ^a   Alcigir, Gunay ^b   Serdar, Muhittin ^a   Mas, Nuket ^c   Isik, Ahmet T ^a   Ates, Yuksel ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Cirrhosis; Hepatic stellate cell; Liver fibrosis; MMPs; Pegylated interferons; TIMPs; Ursodeoxycholic acid

Indexed keywords

COLLAGENASE 3; HYDROXYPROLINE; PEGINTERFERON ALPHA2B; SMOOTH MUSCLE ACTIN; URSODEOXYCHOLIC ACID;

ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HISTOPATHOLOGY; LIVER CELL; LIVER FIBROSIS; MALE; NICK END LABELING; NONHUMAN; PROTEIN LOCALIZATION; RAT; SCORING SYSTEM; STELLATE CELL; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ACTINS; ANIMALS; ANTIVIRAL AGENTS; APOPTOSIS; CHOLAGOGUES AND CHOLERETICS; COLLAGENASES; DRUG THERAPY, COMBINATION; HYDROXYPROLINE; IN SITU NICK-END LABELING; INTERFERON ALFA-2B; KUPFFER CELLS; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MATRIX METALLOPROTEINASE 13; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; URSODEOXYCHOLIC ACID;

EID: 33646012956     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01210.x     Document Type: Article

References (48)

1. Gressner A M. The cell biology of liver fibrogenesis - an imbalance of proliferation, growth arrest and apoptosis of myofibroblasts. Cell Tissue Res 1998; 292: 447-52.
2. Friedman S L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-50.
3. Iredale J P. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001; 21: 427-36.
4. Iredale J P, Benyon R C, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998; 102: 538-49.
5. Perez-Tamayo R, Montfort I, Gonzalez E. Collagenolytic activity in experimental cirrhosis of the liver. Exp Mol Pathol 1987; 47: 300-8.
6. Takahashi S, Dunn M A, Seifter S. Liver collagenase in murine schistosomiasis. Gastroenterology 1980; 78: 1425-31.
7. Benyon R C, Iredale J P. Is liver fibrosis reversible? Gut 2000; 46: 443-6.
8. Kossakowska A E, Edwards D R, Lee S S, et al. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am J Pathol 1998; 153: 1895-902.
9. Lichtinghagen R, Breitenstein K, Arndt B, Kubacher T, Boker K H. Comparison of matrix metalloproteinase expression in normal and cirrhotic human liver. Virchows Archiv 1998; 432: 153-8.
10. Knittel T, Mehde M, Kobold D, Saile B, Dinter C, Ramadori G. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: Regulation by TNF-alpha and TGF-beta1. J Hepatol 1999; 30: 48-60.
11. Iredale J P, Murphy G, Hembry R M, Friedman S L, Arthur M J. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver. J Clin Invest 1992; 90: 282-7.
12. Herbst H, Wege T, Milani S, et al. Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis. Am J Pathol 1997; 150: 1647-59.
13. Yoshiji H, Kuriyama S, Miyamoto Y, et al. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 2000; 32: 1248-54.
14. Wright M C, Issa R, Smart D E, et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001; 121: 685-98.
15. Issa R, Williams E, Trim N, et al. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 2001; 48: 548-57.
16. Saile B, Knittel T, Matthes N, Schott P, Ramadori G. CD95/CD95L-mediated apoptosis of the hepatic stellate cell. A mechanism terminating uncontrolled hepatic stellate cell proliferation during hepatic tissue repair. Am J Pathol 1997; 151: 1265-72.
17. Gong W, Pecci A, Roth S, Lahme B, Beato M, Gressner A M. Transformation-dependent susceptibility of rat hepatic stellate cells to apoptosis induced by soluble Fas ligand. Hepatology 1998; 28: 492-502.
18. Murphy F R, Issa R, Zhou X, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 2002; 277: 11069-76.
19. Baroni G S, D'Ambrosio L, Curto P et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 1996; 23: 1189-99.
20. Powrie F, Coffman R L. Cytokine regulation of T-cell function: Potential for therapeutic intervention. Immunol Today 1993; 14: 270-4.
21. Yagura M, Murai S, Kojima H, Tokita H, Kamitsukasa H, Harada H. Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: Including quantitative assessment by a morphometric method. J Gastroenterol 2000; 35: 105-11.
22. Sobesky R, Mathurin P, Charlotte F, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view. The Multivirc Group. Gastroenterology 1999; 116: 378-86.
23. Guido M, Rugge M, Chemello L, et al. Liver stellate cells in chronic viral hepatitis: The effect of interferon therapy. J Hepatol 1996; 24: 301-7.
24. Manns M P, Mchutchison J G, Gordon S C, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001; 358: 958-65.
25. Lindsay K L, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
26. Zeuzem S, Feinman S V, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.
27. Angulo P, Batts K P, Therneau T M, Jorgensen R A, Dickson E R, Lindor K D. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999; 29: 644-7.
28. Corpechot C, Carrat F, Bonnand A M, et al. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32: 1196-9.
29. Rodrigues C M, Fan G, Ma X, Kren B T, Steer C J. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998; 101: 2790-9.
30. Guicciardi M E, Gores G J. Is ursodeoxycholate an antiapoptotic drug? Hepatology 1998; 28: 1721-3.
31. Hernandez-Munoz R, Diaz-Munoz M, Lopez V, et al. Balance between oxidative damage and proliferative potential in an experimental rat model of CCl 4 -induced cirrhosis: Protective role of adenosine administration. Hepatology 1997; 26: 1100-10.
32. Bergman I, Loxley R. Two improved and simplified methods for the spectrophotometric determination of hydroxyproline. Anal Chem 1963; 35: 1961-5.
33. Bonis P A, Friedman S L, Kaplan M M. Is liver fibrosis reversible? N Engl J Med 2001; 344: 452-4.
34. Nagase H, Woessner J F Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4.
35. Docherty A J, Lyons A, Smith B J, et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 1985; 318: 66-69.
36. Kikuchi K, Kadono T, Furue M, Tamaki K. Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts. J Invest Dermatol 1997; 108: 281-4.
37. Guedez L, Stetler-Stevenson W G, Wolff L, et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 1998; 102: 2002-10.
38. Li G, Fridman R, Kim H R. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 1999; 59: 6267-75.
39. Goldring M B, Sandell L J, Stephenson M L, Krane S M. Immune interferon suppresses levels of procollagen mRNA and type II collagen synthesis in cultured human articular and costal chondrocytes. J Biol Chem 1986; 261: 9049-55.
40. Smith D D, Gowen M, Mundy G R. Effects of interferon-gamma and other cytokines on collagen synthesis in fetal rat bone cultures. Endocrinology 1987; 120: 2494-9.
41. Jimenez S A, Freundlich B, Rosenbloom J. Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest 1984; 74: 1112-6.
42. Sen G C, Lengyel P. The interferon system. A bird's eye view of its biochemistry. J Biol Chem 1992; 267: 5017-20.
43. Muriel P, Castro V. Dose-response studies of interferon-alpha 2b on liver fibrosis and cholestasis induced by biliary obstruction in rats. Pharmacology 1997; 54: 179-85.
44. Rodriguez-Fragoso L, Gonzalez M P, Muriel P. Interferon-alpha 2b increases fibrolysis in fibrotic livers from bile duct ligated rats: possible participation of the plasminogen activator. Pharmacology 1995; 51: 341-6.
45. Fort J, Pilette C, Veal N, et al. Effects of long-term administration of interferon alpha in two models of liver fibrosis in rats. J Hepatol 1998; 29: 263-70.
46. Qiao L, Yacoub A, Studer E, et al. Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes. Hepatology 2002; 35: 779-89.
47. Boucher E, Jouanolle H, Andre P, et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. Hepatology 1995; 21: 322-7.
48. Fabbri C, Marchetto S, Pezzoli A, et al. Efficacy of ursodeoxycholic acid in association with alpha-interferon for chronic hepatitis C in alpha-interferon non-responder patients. Eur J Gastroenterol Hepatol 2000; 12: 511-5.